Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulranumab for cancer-related pain
NCT00929188Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2009
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of fulranumab in cancer pain, sponsored by Janssen Pharmaceutical. Started Oct 2009; status: completed.
02
Drugs
fulranumab
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT00929188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00929188.